Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL3969814 | 0.79 | ALDH1A1 (0.42) | KCNH2TMEM97CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3904820 | 0.78 | ALDH1A1 (0.48) | KCNH2TMEM97CYP1A2CYP2D6CYP2C19 | |
| Formic Acid SCHEMBL3969807 | 0.76 | CYP2C19 (0.39) | KCNH2TMEM97CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3913629 | 0.75 | CYP2C19 (0.42) | CYP1A2CYP2D6CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL18542005 | 0.70 | SMN1; SMN2 (0.51) | CYP1A2CYP2C19SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3913681 | 0.64 | SMN1; SMN2 (0.44) | SMN1; SMN2CHRM2MEN1KMT2A | |
| SCHEMBL7855536 | 0.64 | CYP2C19 (0.53) | KCNH2TMEM97CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5268968 | 0.63 | SMN1; SMN2 (0.70) | KCNH2CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL2168415 | 0.63 | SMN1; SMN2 (0.70) | KCNH2CYP1A2CYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL19685408 | 0.61 | CYP2C19 (0.58) | KCNH2TMEM97CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658072-A4 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-10-09 | — | — | US | disclosed |
| US-7408068-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1658072-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020991-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | KCNH2 1520/4885TMEM97 1415/4885RXFP1 192/4885 |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | KCNH2 1520/4885TMEM97 1415/4885RXFP1 192/4885 |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | APP, BACE1, PSEN1 | KCNH2 1520/4885TMEM97 1415/4885RXFP1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.